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1. Introduction 
Lyme borreliosis is a world-wide multi-organic disease caused by spirochete Borrelia 
burgdorferi sensu lato. Numerous gene-species Borrelia are identified with a various 
frequency in Europe, Asia and America (Ruderko, et al., 2009; Siegel, et al., 2008; Stanek G, 
2011; Wilske, et al., 2007 Wodecka, 2006a). Within the last few years, as well as in Europe as 
in North America, there were prepared strategies, directives and guidelines for diagnostics 
and treatment of Lyme disease, including the frequency of occurrence of specific gene-
species and a specification of clinical symptoms (Center for Disease Control and Prevention 
[CDC], 2011; European Concerted Action on Lyme Borreliosis [EUCALB], 2008). Lyme 
disease seems to be easy to diagnose and treat due to the pathogenic factor known for a 
long-time and elaborated diagnostic and therapeutic schemas. In serological diagnostics an 
impediment constitutes a wide range of genospecies B. burgdorferi, changes of expression of 
particular genes occurring in various stages of an infection, and cross reactions which occur 
in the presence of other pathogenic microorganisms and disease entities connected with an 
immune response disorders. It is connected with the necessary use of appropriately 
configured diagnostic tests and recombinant proteins common for particular genospecies 
and related to the immunological response at different stages of the infection (EUCALB, 
2008; Zajkowska, et al., 2006a,2006b). As well as a diagnostician as a doctor has to consider 
not only the results of the serological tests but also numerous, coexisting, frequently 
unspecified factors in order to make an accurate diagnose confirming or excluding B. 
burgdorferi infection. In many cases, even early and accurate diagnosis and antibiotic therapy 
appropriately applied does not guarantee the effective eradication of a pathogen, and what 
is important for a patient - a complete elimination of symptoms of the disease. Post-
treatment Lyme disease Syndrome (PTLDS) has been confirmed in some patients – it is a 
complex of lingering, unspecified clinical symptoms which impede a complete physical and 
mental recovery in patients after being treated from Lyme disease. This is a crucial problem 
as well as in health as in social life which is frequently ignored. The symptoms concerning 
Lyme arthritis and neuroborreliosis are frequently the cause of an immense disability in 
patients in numerous life activities and it is required to undertake a rehabilitation program 
(Tokarska-Rodak et al., 2007). 
www.intechopen.com
 
Lyme Disease 
 
80
2. Two-step laboratory testing process in diagnostics of Lyme disease 
European Concerted Action on Lyme Borreliosis (EUCALB) and Center for Disease Control 
and Prevention (CDC) recommend a two-step testing process in serological diagnostics of 
Lyme disease (CDC, 2011; EUCALB, 2008). It has been assumed that, a diagnosis of every 
form of clinical disease, except erythema migrans (EM), requires the two-step testing 
process. The first step in the testing process uses enzyme immunoassay techniques: Indirect 
Immunofluorescence Assay (IFA) or Enzyme Linked Immunosorbent Assay (ELISA) in 
order to detect the presence of specific antibodies IgM and/or IgG (in relation to the stage of 
illness). ELISA or IFA tests should be confirmed by immunobloting (Western blot, Wb). In 
other European countries and the USA a two test procedure is recommended: a sensitive 
screening test such as ELISA supported by immunoblot. All specimens positive or equivocal 
by a ELISA or IFA should be tested by a standardized Western blot. Specimens negative by 
a sensitive ELISA or IFA need not by tested further. It was recommended that an IgM 
immunoblot be considered positive if two of the following three bands are present – OspC, 
(24 kDa), BmpA (39 kDa) and Flagelina (41 kDa). It was further recommended that an IgG 
immunoblot be considered positive if bands for antigen proteins are present: p17, p18, p21 
(DbpA), OspC (p22, 23, 24, 25), OspD (p29), p30, OspA (p31), OspB (p34), p58, p83/100 and 
VlsE (Aberer, 2007; Deutsche Borreliose-Gesellschaft e.V, 2010; EUCALB, 2008, MMWR, 
1995). Complete standardization of immunobloting protocols in Europe is unrealistic at 
present. Lyme borreliosis is not the same in all geographic areas due to different local 
prevalence of species and strains of B. burgdorferi s.l. and to heterogeneity within those 
strains. Recommendations for the interpretation of Western blots have not always been 
applicable to populations in geographic areas other than where they were developed. The 
development of immunoblots using defined recombinant or synthetic antigens is promising 
for the future (EUCALB, 2008; Robertson, 2000). 
The test for Lyme disease (ELISA, IFA, Western blot) measures antibodies made by white 
blood cells in response to infection. The antibodies IgM are produced in human’s body in 
the response against the antigen proteins B. burgdorferi in the 2nd-4th week since the EM 
exposure, reaching the ultimate in the 4th-6th week, and they are most frequently IgM anti-
OspC and anti-p41. If the serological test is made too soon, it can show falsely negative 
results in the scope of the presence of IgM because of the low symptomatic features. 
Antibody response in early Lyme borreliosis may by weak or absent, especially in erythema 
migrans and antibiotic treatment may abrogate antibody production. Serology may also be 
negative in acute neuroborreliosis with short duration of the disease (EUCALB, 2008; Stanek, 
2011). The repetition of Wb after 2-4 weeks should be considered in patients at an early stage 
in case of a positive result of an enzyme immunoassay test and negative confirmation test 
(Depietropaolo, et al., 2005; EUCALB, 2008; Flisiak& Pancewicz, 2011; Przytuła, et al., 2006). 
When Western blot is used during the first 4 weeks of disease onset (early Lyme disease), 
both IgM and IgG procedures should be performed (MMWR, 1995). Specific IgG and/or 
IgM are found in only 40-60% of untreated cases EM, particularly in patients with signs 
haematogenous spread (EUCALB, 2008).  In most patients with an active Lyme disease, the 
level of the antibodies IgM decreases after about 4 months. The antibodies IgG start to 
emerge in a serum in the 4th week since the infection.  In the early disseminated stage or the 
acute neuroborreliosis, the IgM/IgG seropositiveness increases 70-90%. In this period, the 
immunological response can be manifested in relation to few antigens. For the diagnosis 
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Fig. 1. Western Blot interpretation of IgM/IgG class antibodies against specific antigens plus 
recombinant VlsE Borrelia burgdorferi (according to Euroimmun). 
of Lyme arthritis, it is essential to demonstrate the presence of specific IgG antibodies, 
usually in high levels. A positive IgM test in the absence of IgG antibodies argues against 
the diagnosis of Lyme arthritis. Follow-up is recommended only in cases with short 
duration of symptoms. For the diagnosis of acrodermatitis chronica atrophicans (ACA), it is 
essential to demonstrate high levels of IgG anti-B. burgdorferi. A positive IgM test in the 
absence of IgG antibodies argues against the diagnosis of ACA (EUCALB, 2008). Technical 
problems that contribute to false-negative or false-positive results include the adoption of 
inadequate cut-off levels, the presence of cross-reacting antibodies, false positive reactions 
caused by some autoimmune diseases and inappropriate interpretation criteria for Western 
blots (Stanek, 2011). Results are considered positive only if the ELISA/IFA and the 
immunoblot are both positive. CDC does not recommended skipping the first test and just 
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doing the Western blot. Doing so will increase the frequency of false positive results and 
may lead to misdiagnosis and improper treatment (CDC, 2011). According to the directives, 
which are mandatory in Europe, the serological tests determining the level of antibodies 
IgM/IgG anti-Borrelia burgdorferi should not be used in the assessment of the effectiveness of 
the therapy. The effectiveness of the antibiotic therapy should be assessed only on the basis 
of the dynamics of the clinical picture (EUCALB, 2008; Flisiak & Pancewicz, 2011). It has not 
been defined so far that there is a parameter, which marking would reliably determine the 
effectiveness of the elimination of the pathogen. It has been suggested that, the decrease of 
the titre of the antibodies for C6 protein can be interpreted as an indicator of the 
effectiveness of the therapy (Aberer, 2007). The probability that a patient with a positive 
serological test actually has Lyme borreliosis and the probability that a patient with a 
negative test does not have the disease depends on the performance characteristics of a 
given assay (sensitivity and specificity) and also on the prevalence of the disease in the 
population (Stanek, 2011). Both diagnostic tests (ELISA/IFA and Wb) complement each 
other mutually. Serological diagnosis is always a balance between sensitivity and 
specificity of the assays. A high level of specificity is always more important than a high 
level of sensitivity (EUCALB, 2008). The enzyme immunoassay tests are characterized by 
high sensitivity and relatively low specificity, whereas the Wb test is characterized by 
high specificity and low sensitivity (Flisiak & Pancewicz, 2011). A minimum standard of a 
least 90% specificity for the screening tests (ELISA, IFA) and 95% specificity for the 
immunoblot should be established in the population where the assay is to be used 
(EUCALB,  2008). The two-step laboratory testing process is designed to eliminate 
unspecific falsely positive results which occur in a various frequency during the diagnosis 
with the use of one test and it allows on an explicit assessment with the interpretation of 
the limit results. The PCR methods are not used in a routine diagnosis of Lyme disease on 
account of lack of gained standards, although there are a number of researches done in 
this matter by many research establishments. The detection of bacteria’s DNA made by 
the PCR method can be interpreted in two ways: it can confirm the presence of a living 
bacteria in an organism or it can signify on the presence of DNA coming from bacteria 
killed with antibiotics. The PCR method does not allow on a differentiation of DNA 
between living and dead being, or free DNA coming from the disintegration of the 
bacteria cell (Wodecka, 2006b). 
3. The immunological response against the infection of B. burgdorferi in the 
aspect of clinical symptoms 
The dissemination of the spirochetes into further tissues and organs occurs in a short period 
of time since the transmission of the infection through blood and lymphatic vessels and it is 
possible that through peripheral nerves as well (Sigal, 1997). The innate defense mechanisms 
are initiated as the first in the process of the immunological response of an organism against 
infection, in which as well as phagocytes as complement system, lysozyme and interferon 
take part. All disorders of the unspecific mechanisms in the early stage of the infection can 
prevent from an effective elimination of the pathogen in further stages of the immunological 
response, and consequently lead to the development of a chronic state of the illness 
(Bykowski et al., 2008; Siegel, et al., 2010). The diagnosis of the illness in patients with EM is 
usually made on the basis of a clinical picture without a confirmation of the serological tests, 
which results are frequently negative during this period. The erythema migrans usually 
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exposes in the place of a tick’s bite after 1-3 weeks. Typical EM has a form of a spot with a 
tendency of expanding, a diameter of more than 5 cm and a brightening in the middle. 
Untypical forms do not demonstrate central brightening. They can be shaped irregularly or 
have hemorrhagic features. The exposure of EM within the period of time shorter than 2 
days after a tick’s bite and of a diameter less than 5 cm oppose to the diagnosis. Erythema 
migrans disappear spontaneously within few days since an inception of the antibiotic 
therapy however it does not mean that the infection has been eliminated. The untreated 
lesions can stay even for few months and disappear spontaneously, though the infection still 
lasts (Flisiak & Pancewicz, 2011; Tokarska-Rodak, et al., 2010a, 2010b). It is essential to 
implement the serological test when EM takes the untypical form or does not appear and 
there is a suspicion of the infection with the spirochetes of B. burgdorferi (Zajkowska, et al. 
2006). The symptoms of the disseminated Lyme disease concern: nervous system, heart, 
muscles and joints (Aberer, 2007; Depietropaolo, 2005). This stage of the disease appears 
within a few weeks till more than a year since the infection, while the late stage of Lyme 
disease can occur even many years after the invasion of Borrelia spirochetes into human 
body. The late stage of Lyme disease is manifested with skin lesions (acrodermatitis 
chronica atrophicans), chronic neurological symptoms or chronic arthritis. Borrelia arthritis 
can take on a chronic form leading to a permanent joint damage, and it can also be 
manifested by: chronic and migrating muscle pains, recurring arthritis, a pain caused by an 
inflammatory reaction within the scope of motor organs and the weakening of skeletal 
muscles (Singh, & Girschick, 2004a; Wilgat, et al., 2004). The presence of IgG for the broad 
antigen spectrum is observed in persons with symptoms of late Lyme disease, in 100% of 
patients (EUCALB, 2008; Wilske, et al., 2007). The examination of cerebrospinal fluid is 
made in the diagnostics of neuroborreliosis. The presence of antibodies anti-B. burgdorferi in 
the cerebrospinal fluid cannot result from their production in the cerebral space but it can be 
an effect of the penetration of antibodies from blood through the damaged barrier blood-
brain (EUCALB, 2008). The decision concerning the diagnosis and treatment of Lyme 
disease is based on the clinical picture with the results of serological rests taken into 
account. Lyme disease should not be considered in case of the positive results of the tests 
and without the presence of clinical symptoms of the disease. Although, it is possible that 
there is a certain percentage of people in a healthy population, in whom the seropositiveness 
changing along with the age is observed in comparison with B. burgdorferi connected with 
outdoor activities (Bacon, et al., 2003; Wilske, et al., 2007).  
4. The immunological response against B. burgdorferi infection in the aspect 
of the diversity of genospecies  
There are two risk factors of acquiring infection Borrelia in a relation to existence on the area 
where the ticks are present. The first concerns the estimation of spreading B. burgdorferi 
sensu lato in ticks Ixodes ricinus which is the main vector of pathogen in Europe. The second 
factor concerns the determination of diversity of gene-species on a particular area. The risk 
of human infection B. burgdorferi s.l increases along with the number of ticks being infected 
on a particular area. It depends from the multiple of stabs during the haematophagy season 
of ticks and it becomes bigger when the time of infected ticks present on a human skin is 
longer (Ołdak, et al., 2009; Wodecka, 2006a).  The molecular analysis has shown that isolates 
of Borrelia burgdorferi are genetically and phenotypically diversified, hence the group of 
www.intechopen.com
 
Lyme Disease 
 
84
species closely related of genus Borrelia were defined as Borrelia burgdorferi sensu lato. The 
complex of Borrelia burgdorferi sensu lato encompasses at least 12 species: B. burgdorferi 
sensu stricto, B. garinii, B. afzelii, B. spielmani, B. valaisiana, B. lusitaniae, B. japonica, B. 
andersonii, B. tunukii, B. turdae, B. bissettii and B. sinica (Aguero-Rosenfeld et al., 2005; 
Ruderko, et al., 2009; Sicklinger, et al., 2003; Wodecka, 2006a). According to some sources, 
there are also B. californiensis sp. nov. in this group (Siegel, et al., 2008). B. afzelii, B. garinii, 
B. burgdorferi sensu stricto and occasionally B. spielmani, B. valaisiana, B. lusitaniae are 
responsible for causing Lyme disease in Europe whereas in South America only B. 
burgdorferi sensu stricto (Siegel, et al., 2008; Stanek G, 2011; Wilske, et al., 2007). Even 
though Lyme disease is most generally caused in Europe by the above mentioned three 
genospecies Borrelia, it cannot be excluded that there are other genospecies causing the 
symptoms of the disease. DNA of B. valaisiana was detected in the cerebrospinal fluid of a 
patient with chronic neuroborreliosis in Greece and in a patient with erythema migrans. B. 
lusitaniae was isolated from a patient with suspected Lyme disease in Portugal (Derdáková 
& Lenčáková, 2005). Direct relation of skin changes of erythema migrans (EM) type with an 
infection of B. spielmani was revealed in some of the European countries (Netherlands, 
Germany, Hungary, Slovenia). Thus, the relation of these gene-species with Lyme disease 
has been proven (Maraspin, 2006; Wilske, et al., 2007). The genetic changeability of Borrelia 
has an influence as well as on the spirochetes’ pathogenicity as on the clinical manifestations 
of the disease. Consequently, the heterogeneity of microorganisms causing Lyme disease in 
Europe should be taken into consideration in the serological and microbiological diagnostics 
(Derdáková & Lenčáková, 2005; Richter et al., 2004; Wang et al., 1999; Wilske, et al., 2007). It 
has been proven that Borrelia afzelii is responsible for skin lesions of type acrodermatitis 
chronica athropicans (ACA) and the presence of borrelia lymphocytoma, whereas B. garinii 
has been isolated more frequently from the cerebrospinal fluid and thus its relation with 
neuroborreliosis is emphasized. B. burgdorferi s.s. is responsible for lesions type arthritis. 
As well as the late skin lesions as neuroborreliosis are more often detected in Europe 
whereas Lyme arthritis is more often diagnosed in the USA (Derdáková & Lenčáková, 2005, 
Wilske, et al., 2003, 2007). All three genospecies B. burgdorferi s.s., Borrelia afzelii and Borrelia 
garinii can participate in the development of erythema migrans. However, there are 
differences present in the clinical manifestation of EM caused by those genospecies 
(Maraspin, 2006; Wodecka, 2006a). According to the serological diagnostics, it is essential to 
notice whether antibodies IgM/IgG, which are produced in the autoimmune response 
against the infection caused by other genospecies than those three known as pathogenic in 
Europe, can be detected by diagnostic tests used in a standard diagnostics of Lyme disease. 
The problem, among many other things, concerns infections caused only by B. spielmani. 
The results showing that there is a possibility of the infection caused by few genospecies B. 
burgdorferi s.l. has been obtained in the analysis of the presence of antibodies for antigen 
proteins OspC and p18 of four genospecies B. burgdorferi s.s., B. afzelii, B. garinii and B. 
spielmani in patients with symptoms of Lyme arthritis from Eastern Poland (Tokarska-
Rodak, et al., 2010c). The identification of antibodies anti- OspC B. spielmani seems to be 
extremely important considering previous stage of immunological answer when only 
antibodies IgM anti-OspC are frequently present without antibodies of IgG class. In the case 
of infection with only one gene-species, the identification of antibodies IgM anti-OspC can 
be the only chance in the early identification of the infection with the lack of skin symptoms 
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as EM.  Diagnostic tests used routinely in the Lyme disease diagnosis in Europe (ELISA, 
Western blot) usually have antigen extracts of B. burgdorferi s.s., B. afzelii, B. garinii or 
electrophoreticaly separated antigen extracts of Borrelia afzelii enriched with recombinant 
VlsE antigen. According to researchers, the  antigens B. spielmani – gene-species, which 
researchers mentioned as the fourth next to B. burgdorferi s.s., B. afzelii, B. garinii, should be 
additionally used in the tests and be considered in the diagnosis of Lyme disease within 
Europe (Derdáková & Lenčáková, 2005; Maraspin, 2006; Tokarska-Rodak, et al.,  2010c).  
4.1 The antigen proteins B. burgdorferi diagnostically significant 
In the clinical practice the evaluation of the active stage of infection is primarily based on 
the clinical symptomatology, routine enzyme immunoassays, and confirmatory tests such 
as Western Blot (CDC, 2011; Štefančikowá, et al., 2005; Tokarska-Rodak, et al., 2010a). The 
identification of the antibodies IgM and IgG directed against specific antigenic proteins B. 
burgdorferi constitutes the basis of the serological diagnostics of Lyme disease. It becomes 
essential in Europe to use tests with appropriately selected antigenic panel considering 
the heterogeneity of the proteins Borrelia burgdorferi (Štefančiková, et al., 2005). The 
evolution of a production of the antibodies directed against various antigens B. burgdorferi 
is observed along with the development of the disease process after the transmission of 
the spirochetes into human body. In the early stage of the infection (2 to 4 weeks) the 
immunological system detects only few antigens Borrelia as p41 (flagellin) and proteins 
Osp and produces the antibodies IgM against them. OspC is an immunogenic lipoprotein 
and main virulent factor of the infection in people (particularly genotypes OspC A, B, I, K). 
OspC poorly succumbs to an expression in a tick’s bowels and in a cultivation, however it 
undergoes intensively only after the transmission of a spirochete into a mammal organism. 
OspC and OspA are the most important proteins of the outer membrane in the cell of B. 
burgdorferi. OspC is characterized by large polymorphism and a substantial reactivity in 
comparison with OspA. Both antigens are connected with genetic and antigen 
heterogeneity among various species. The classification is made on the basis of various 
genotypes or serotypes. There have been 8 different serotypes OspA and 16 serotypes 
OspC (B. burgdorferi s.s 6 serotypes, B. afzelii 4 serotypes, B. garinii 6 serotypes) registered 
in Europe (Aberer, 2007; Wodecka, 2006a). The surface proteins of a spirochete affect 
significant stages of the immunological response: OspA inhibits the spirochetes’ 
phagocytosis and an oxygen explosion in neutrophils especially at the low concentration 
of a complement, which substantially simplifies the survival and the dissemination of 
bacteria. The spirochetes can bind with the receptor cells molecules of a host and the 
extracellular matrix as integrins, glycoproteins, and proteoglycans (Hartiala, et al., 2008). 
The antibodies IgG anti-B. burgdorferi appears after several weeks since the bite, and their 
level can remain increased and continue even after the resolution of the clinical symptoms. 
As far as the infection develops, the immunologic response extends on the increasing 
number of antigen proteins –p83, p58, p53, p43, p39, BBK32 (p35), p31, p30 (OspA), p25 
(OspC), p21, p19, DbpA (p17). The recombinant antigens OspC, p100, VlsE, DbpA (p17), 
BBK32p66, peptides C10 and C6 are used in order to improve the diagnostics of Lyme 
disease and for a better prediction of the duration of the infection (Aberer, 2007; Aguero-
Rosenfeld et al., 2005; Tokarska-Rodak, et al., 2008, 2010a; Wilske, et al., 2007). The 
selected antigens such as p83/100, BmpA (p39) or antigens of high specificity but 
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common for many microorganisms (e.g. the protein of flagellum- flagellin) are introduced. 
Flagellin (p41) is one of the most immunogenic protein which occurs in the cell of B. 
burgdorferi and causes very strong and early humoral response. Epitopes, which are 
characteristic for B. burgdorferi, only occur between 129 and 251 aminoacid. The protein 
which comes from the initial and final part of the chain shows a high degree of the 
homology with the sequence of flagellin’s aminoacids Bacillus subtilis (65%) and Salmonella 
Typhimurium (56%). The use of the parts only specific for B. burgdorferi in diagnostic tests has 
an influence on the decrease of the percentage of results falsely positive, especially for IgM 
(Aguero-Rosenfeld, et al., 2005). Other sensitive and specific antigen which may be used in 
the serological confirmation of the infection is DbpA (p17). Its presence was confirmed in 
93% of patients with Lyme arthritis and in 100% of patients with neuroborreliosis (Aberer, 
2007). As indicated by the diagnostics of infections caused by B. burgdorferi s. l., the essential 
antigens are highly immunogenic proteins developing in vivo after the spirochetes’ 
transmission into human body.  The antigens VlsE,  BBA 36 (22kDa), BBO 323 (42 kDa), 
Crasp 3 (21 kDa), pG (22 kDa) show the expression in vivo and contain highly immunogenic 
epitopes common for B. burgdorferi sensu lato, which are an important determinant for an 
advanced stages of Lyme disease in the serology of IgG (Bykowski, et al., 2007; Hofmann, et 
al., 2006; Tokarska-Rodak, et al., 2010a, Wilske, et al., 2007, Zajkowska et al., 2006b). The 
researchers believe VlsE protein is the most sensitive recombinated B. burgdorferi s.l. antigen 
used in the diagnostics. It is possible to detect IgM/IgG anty-VlsE in all pathogenic Borrelia 
burgdorferi sensu lato genospecies and the risk of false positive results is ten times lower in 
comparison to other Borrelia antigens (Chmielewska-Badora et al., 2006, Liang et al., 2000, 
Wilske, et al., 2007). In spite of an advanced stage of Lyme disease in some patients, there 
can be the continuity of the antibodies IgM in relation to the outer superficial protein 
OspC and VlsE (Hofmann, 2006, Tokarska-Rodak, 2010a). As far as antigen VlsE currently 
occurs in mostly used serological test ELISA and Western blot, the other antigens are not 
included into routine diagnostics. There are highly immunogenic proteins CRASPs 
(complement regulator-acquiring surface proteins) found beside antigen VlsE during the 
infection of B. burgdorferi e.g. CRASP-3, proteins belonging to Erp family (pG), and lots of 
membrane proteins (immunogenic membrane-associated proteins) among which there is 
BBO323 (Nowak, et al., 2006; Singh & Girschick, 2004a). The researches confirm the 
significance of the antigens in vivo in the immunological response against the infection B. 
burgdorferi. The researches conducted by Hofmann and his associates shown that antigens 
BBA36, BBO323, Crasp3, pG are characteristic for the late infections of Borrelia. It has 
been confirmed that there are the antibodies IgG for BBO323 (90%), BBA36 (67%), p83 
(71%) in patients with Lyme arthritis but very seldom antibodies for Crasp3 (38%) and pG 
(33%) (Hofmann, et al., 2006). The presence of the antibodies IgG anty–VlsE, Crasp3, 
BBO323, BBA36 has been confirmed with various frequency in patients bitten many times 
by ticks and with clinical manifestation of Lyme arthritis (Tokarska-Rodak, et al., 2008, 
2010a). The presence of antibodies IgG for VlsE and BBO323 have also been confirmed in 
persons being suspected of the disease, who had erythema migrans (Zajkowska, et al., 
2006a, 2006b). It has been assumed that, the routine use of a broaden spectrum of the 
antigens in vivo (beside VlsE) in Western blot tests can contribute to the designation of 
the severity and dynamics of the immunological response against the used antigens, what 
will provide more possibilities in the assessment of the immune reactions in relation to a 
clinical state of a patient.  
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5. The immunological factors essential in the response of a hosts’ organism 
against the infection of B. burgdorferi 
In the light of the current knowledge, some diseases and infections are started to be 
considered in the aspect of probable disfunctions in the control of functioning of the 
elements of immunological system, including complement system. It allows to look from a 
different perspective on many disease entities, which are caused by infections of particular 
pathogenic microorganisms (Klaska, & Nowak, 2007).  
5.1 The complement system 
The dissemination of spirochetes Borrelia in the human organism and the development of 
the infection is a complex, omnidirectional process which occurs owing to many 
adjustments and mechanisms allowing bacteria to survive. It seems to be essential that B. 
burgdorferi is able to avoid destructive effect of the congenital defence mechanisms. The 
complement system participates in the elimination of B. Burgdorferi, and its activation on the 
surface of the pathogen leads to the cytolitical damage of bacteria (Bykowski, et al., 2007). 
The disactivation of activation cascades of the complement allows Borrelia to survive and 
also determines a competent reservoir for particular genospecies of bacteria (Siegel, et al., 
2010). There are also other microorganisms apart from Borrelia burgdorferi, like: Echinococcus 
granulosus, Neisseria meningitidis, Neisseria gonorrhoeae, Streptococcus pyogenes, Streptococcus 
pneumoniae, Yersinia enterocolitica, Candida albicans and human immunodeficiency viruses 
which have developed mechanisms allowing to overcome the destructive process of the 
complement system. The acquisition of regulatory molecules of a host allows to avoid an 
adverse effect of the complement (Klaska, & Nowak, 2007). The microorganisms bind the 
human fluid phase complement regulators factor H or FHL-1 and some also bind the clasical 
pathway regulator C4Bp directly to the surface (Krajczy, et al., 2001). Precise analysis in vitro 
within many isolates of three pathogenic genospecies Borrelia burgdorferi s.l. shown that all 
isolates of the same genospecies have similar sensitivity on the complement’s effect, 
however there are significant differences among genospecies. The isolates of B. afzelii are 
particularly resistant to the complement’s effect, the majority of B. burgdorferi s.s. isolates are 
on average sensitive, whereas B. garinii are fundamentally sensitive on the effect of the 
complement system (Suchonen, et al., 2002). It is well known that B. burgdorferi s.s B31, 
which come from North America, are less sensitive on the complement’s effect than those 
which come from Europe. The difference comes from a various capacity to bind component 
C9, which as a result leads to the reduction of the living functions of the spirochetes, and 
morphological changes and the fragmentation of a bacteria cell (Krajczy, et al., 2001). 
Proteins CRASPs (Complement Regulator – Acquiring Surface Proteins) are responsible for 
the ability to disactivate the complement in the case of Borrelia burgdorferi s.l., which are able 
to bind regulatory proteins of an alternative way, and as a result have an influence on the 
inhibition of  the activation cascade of the complement. CRASPs (from CRASP-1 to CRASP-
5) are connected with the soluble forms of the two regulatory proteins – factor H and factor 
H-like protein 1 (FHL-1) and hence the activation of the complement on the surface of 
bacteria does not occur. A lot of strains of B. afzelii and some of B. burgdorferi s.s. are capable 
to control the alternative way of the complement through the absorption of FHL-1 and H 
molecules. That kind of capability does not have B. garinii which are sensitive on the 
complement’s effect (Krajczy,  et al.,  2001; Suchonen, et al., 2002; Zajkowska, et al., 2006c). 
Serum resistance of B. burgdorferi B31 is mainly associated witch CRASP-1 and mediated by 
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binding of complement regulator factor H. OspA and OspC do not bind factor H (Hartiala, 
et al., 2008). Regardless of the way on which the activation of the complement occurs, the 
development of  the membrane – attack complex (MAC) is a key stage. The researches 
indisputably confirmed the significance of the complement in the bacteriolysis of Borrelia. 
The spirochetes induce oxidative burst and calcium mobilization and are susceptible to 
phagocytosis dependent on the complement (Suchonen, et al.,  2000, 2002; Krajczy, et al., 
2001). The lack of susceptibility to the effect of the mechanisms of innate immunity, end 
especially the immunity on the destruction with the use of the complement, is determined as 
the virulent factor of Borrelia burgdorferi (Siegel,  et al., 2010). 
5.2 Lyme disease in the aspect of the autoimmunological processes 
The researchers name the long duration of the disease as one of the risk factors of the 
occurrence of Borreliosis which is not curable. One cannot exclude the possibility that the 
long lasting infection of B. burgdorferi, next to typical symptoms of Lyme disease, may also 
induce the autoimmunological changes in a small percent of patients. The 
autoimmunological processes can contribute to maintain excessive inflammatory response 
in late Lyme disease and can be responsible for the inflammatory reaction maintenance, 
even after the elimination of the pathogen (Grygorczuk, 2008, Kisand, 2007; Singh & 
Girschick, 2004b Wilgat, 2004). In certain conditions of the environmental stress, the 
spirochetes can undergo reversible transformation from the motile and helical into inactive, 
spherical cysts. That kind of forms was observed in the cerebro-spinal fluid and tissues of 
the patients with Lyme disease (Singh & Girschick, 2004b). The metabolically unactive 
alveolar forms of Borrelia (blebs forms) containing lipoproteins OspA, OspB, OspD are 
named as a source of long-term antigen stimulation, which lasts even during the absence of 
bacteria able to multiple (Stere, 2003;  Śpiewak, 2004). The examination of the patients with 
early Lyme disease did not reveal direct connection between the presence of antibodies anti-
Borrelia and antinuclear antibodies (ANA) (Śpiewak, 2004). It is possible that there is a 
relation between the initial diagnosis of Lyme disease as erythema migrans and the 
occurrence in the late stage in a small percentage of people, in spite of the used treatment on 
arthral symptoms with simultaneous presence of the antibodies ANA (Tokarska-Rodak, 
2010b). According to Singh, one potential explanation for antibiotic-resistant Lyme disease is 
the generation of autoimmunity mediated directly or indirectly by the pathogen (Singh, & 
Girschick, 2004b). Apoptosis plays the most important role in the control and physiological 
extinguishing of the inflammatory reaction in the infections, including the infection of B. 
burgdorferi. The impairment of apoptosis of lymphocytes and other leukocytes can be 
connected with the risk of autoimmunization (Grygorczuk, 2008). 
5.3 Problems in the diagnosis of Lyme disease are connected with the occurrence of 
other disease entities 
There are many disease states which presence should be considered while interpreting the 
results of the screening tests and the confirmation tests in the direction of Lyme disease. The 
antibodies present in the serum of people infected with EBV, CMV or Mycoplasma can react 
crosswise with the antigens of B. burgdorferi e.g. p41, OspC, BmpA (p39) which direct the 
diagnostic proceedings in a wrong direction. The antibodies of the cross-reaction for 
antigens OspC, p39 B. burgdorferi were also observed in the samples with serum of patients 
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with the infection Treponema pallidum, Herpes simplex virus (HSV) type 2 (Depietropaolo et 
al., 2005; Strasfeld, et al., 2005). The antigen Epstein Barr VCA-gp125 (Virus Capsid Antigen) 
together with antigens B. burgdorferi were applied in one of the WB tests used in the 
diagnostics of Lyme disease. Mononucleosis should be excluded in the mode of various 
diagnosis in the case when there is a reactivity against EBV-gp125 next to reactivity IgM 
against specific proteins Borrelia. It is widely acknowledged that in persons with 
autoimmune diseases carried with high index of auto-antibodies (hypergam-
maglobulinemia), it is necessary to consider the possibility of obtaining falsely positive 
results in Lyme disease serodiagnostics (EUCALB,  2008; Flisiak & Pancewicz, 2011).  The 
denotations of the antibodies anti-B. burgdorferi conducted by Hofmann et al in patients with 
autoimmune diseases revealed a possibility of the occurrence of the cross-reaction and the 
obtainment of falsely positive results pointing to the existence of Lyme disease in this group 
of patients (Hofmann, et al., 2006). Multiple sclerosis, lupus erythematosus can give positive 
results, especially when the test which is used in order to determine the level of IgM anti-B. 
burgdorferi is based on sonicate antigens (EUCALB, 2008). Due to the growing number of 
people diagnosed in the direction of Lyme disease, the problem concerning the results 
falsely positive resulting from the cross reactions seems crucial, especially as regards to 
people whose symptoms of Lyme disease are unspecific and slightly intensified. Thus, in 
order to decrease its percentage in the largest extent, the available possibilities of diagnostics 
should be used. 
5.4 Post - Treatment Lyme Disease Syndrome (PTLDS) 
About 10-20% of patients with the diagnose of Lyme disease suffers from the clinical 
symptoms of constant, repeating or persistent capacity from few months to a year after the 
use of appropriate antibiotic therapy. The symptoms are nonspecific:  muscle and joint 
pains, cognitive defects, increased fatigue, irritability, emotional lability, disturbances in 
sleep, concentration, and memory (Feder, et al., 2007). In that kind of cases, the clinical and 
laboratory assessment aims to exclude the possibility of treatment failure or the presence of 
a new condition unrelated to previous Lyme borreliosis. That kind of state is defined as 
post-treatment Lyme disease syndrome (PTLDS) if it is characterised by the presence of 
persistent symptoms syndrome and lasts longer than 6 months since the treatment. PTLDS 
cannot be defined as “chronic” Lyme disease, and the occurrence of the symptoms 
mentioned above do not justify the use of antibiotic therapy, which in these cases is useless 
and potentially harmful for the patient with PTLDS. The use of symptomatic treatment is 
recommended for the patients with PTLDS (CDC, 2011; Stanek, et al., 2011). The reason of 
the occurrence of PTLDS is not entirely explained. It has been assumed that lingering 
symptoms are due to residua damage to the tissues and immune system that occurred 
during the infection. Similar complications and auto-immune responses are known to occur 
following other infectious diseases (CDC, 2011; Seidel, et al., 2007). 
6. Conclusion 
Highly immunogenic proteins produced in vivo after spirochete transmission into the 
human body are significant antigens for the diagnostics of B. burgdorferi s.l. infections. 
Antigens VlsE, BBA36, BBO323 and Crasp 3 demonstrate in vivo expression and comprise 
highly immunogenic epitopes, common for B. burgdorferi s.l., which are important IgG 
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serological markers of advanced stages of borreliosis. Thus a serologic test with those 
antigens involved creates better potential to evaluate immune response with account for 
clinical status of the patient. The detection of antibodies directed against specific B. spielmani 
antigens suggests that this microorganism may be responsible for triggering borreliosis both 
as a single etiologic agent and with other Borrelia genospecies. The long-lasting persistence 
of the disease and thus long-term antigenic stimulation can be considered as a factor 
enabling the initiation of autoimmune reactions. This process can exist in a small percentage 
of patients with Lyme disease but the possibility of its inception cannot be completely 
negated. 
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